

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### STA Idelalisib for previously treated chronic lymphocytic leukaemia

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No equality issues were raised during the scoping process.
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No equality issues were raised during submission or in the patient expert statements.
---

- |  |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No equality issues were raised during the Appraisal Committee meeting.
--

- |  |
|--|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for |
|--|

the specific group?
Not applicable.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
Not applicable.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Not applicable.

**Approved by Associate Director (name):** ...Frances Sutcliffe.....

**Date:** 15 June 2015

## **Final appraisal determination**

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
--

Yes. Consultees suggested that the draft recommendations for people with untreated chronic lymphocytic leukaemia and a 17p deletion or TP53 mutation would be unethical because this group have no other treatment options available to them. Severity of disease is not a protected characteristic under equality legislation. Access to treatment is not an equality issue that can be dealt with in a NICE technology appraisal. Following the second appraisal Committee meeting, the Committee concluded to recommend idelalisib with rituximab for this group.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No further equalities issues were identified.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No further equalities issues were identified.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No further equalities issues were identified.

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Not applicable.

**Approved by Centre or Programme Director (name):** .....Meindert Boysen...

**Date:** 7 September 2015

